Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

BackgroundDue to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) in the treatment of major depressive disorder (MDD).AimThe aim of Part A of this study was to evaluate the safety, toler...

Full description

Bibliographic Details
Main Authors: Ellen James, David Erritzoe, Tiffanie Benway, Zelah Joel, Christopher Timmermann, Meghan Good, Claudio Agnorelli, Brandon M. Weiss, Tommaso Barba, Graham Campbell, Michelle Baker Jones, Charlotte Hughes, Helen Topping, Malcolm Boyce, Carol Routledge
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Psychiatry
Subjects:
dimethyltryptamine
major depressive disorder
pharmacodynamic
psychedelic
safety
tolerability
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1305796/full

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1305796/full

Similar Items